Abstract
Background: Because of the low rate of lymph node metastasis in stage I rectal cancer (RC), local resection (LR) can achieve high survival benefits and quality of life. However, the indications for postoperative adjuvant therapy (AT) remain controversial.Methods: A retrospective analysis was performed in 6,486 patients with RC (pT1/T2) using the Surveillance, Epidemiology, and End Results (SEER) database. Patients were initially diagnosed from 2004 to 2016; following LR, 967 received AT and 5,519 did not. Propensity score matching (PSM) was used to balance the confounding factors of the two groups; the Kaplan–Meier method and the log-rank test were used for survival analysis. Cox proportional hazards regression analysis was used to screen independent prognostic factors and build a nomogram on this basis. X-tile software was used to divide the patients into low-, moderate-, and high-risk groups based on the nomogram risk score.Results: Multivariate analysis found that age, sex, race, marital status, tumor size, T stage, and carcinoembryonic antigen (CEA) in the non-AT group were independent prognostic factors for stage I RC and were included in the nomogram prediction model. The C-index of the model was 0.726 (95% CI, 0.689–0.763). We divided the patients into three risk groups according to the nomogram prediction score and found that patients with low and moderate risks did not show an improved prognosis after AT. However, high-risk patients did benefit from AT.Conclusion: The nomogram of this study can effectively predict the prognosis of patients with stage I RC undergoing LR. Our results indicate that high-risk patients should receive AT after LR; AT is not recommended for low-risk patients.
Highlights
Colorectal cancer is the third most common cancer in the world and the second leading cause of cancer death
According to inclusion and exclusion criteria (Figure 1), a total of 6,486 patients were included with local resection (LR) of stage I rectal cancer (RC) before the propensity score matching (PSM), including 5,519 in the non-adjuvant therapy (AT) group and 967 in the AT group
The clinicopathological data showed that AT was significantly correlated with race, marital status, tumor grade, tumor size, T stage, carcinoembryonic antigen (CEA), and perineural invasion (PI) (p < 0.05)
Summary
Colorectal cancer is the third most common cancer in the world and the second leading cause of cancer death. While rectal cancer (RC) accounts for one-third of the colorectal cancer cases, most are distal RC [1, 2]. In the early stage of RC, tumor cells are mostly well-differentiated, the rate of lymph node metastasis is < 10%, complete cure can be achieved through local resection (LR), and LR reduces the perioperative complication rate and mortality [3, 4]. In 1977, Professor Morson [5] of St. Mark’s Hospital in the United Kingdom first published the results of the application of local excision in the treatment of early RC. Because of the low rate of lymph node metastasis in stage I rectal cancer (RC), local resection (LR) can achieve high survival benefits and quality of life. The indications for postoperative adjuvant therapy (AT) remain controversial
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
